Degrading TBK1 to disarm VHL-deficient renal cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Clear cell renal cell carcinoma (ccRCC) with von Hippel-Lindau (VHL) loss is a subtype of kidney cancer.
• VHL-deficient ccRCC exhibits a dependency onTANK-binding kinase 1 (TBK1).
• Targeted therapies for VHL-deficient ccRCC, beyond HIF-2α inhibition, are limited.

Purpose of the Study:

• To develop and evaluate a novel therapeutic strategy targeting TBK1 in VHL-deficient ccRCC.
• To assess the pre-clinical activity of a second-generation cereblon-recruiting TBK1 proteolysis-targeting chimera (PROTAC).

Main Methods:

• Development of a second-generation PROTAC molecule designed to recruit the E3 ligase cereblon.
• Evaluation of the PROTAC's ability to induce degradation of TBK1.
• Assessment of the PROTAC's anti-cancer activity in pre-clinical models of ccRCC.

Main Results:

• The developed PROTAC effectively recruits cereblon and induces TBK1 degradation.
• The TBK1-targeting PROTAC demonstrated promising pre-clinical anti-cancer activity.
• This approach offers a potential new therapeutic avenue for ccRCC.

Conclusions:

• Targeting TBK1 degradation via PROTAC technology is a viable strategy for VHL-deficient ccRCC.
• The second-generation cereblon-recruiting TBK1 PROTAC shows significant pre-clinical potential.
• This research expands therapeutic options for kidney cancer patients with VHL loss.